nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

25.08.2021 | Editorial

PSMA PET-CT: the winner takes it all

verfasst von: Massimo Lazzeri, Arturo Chiti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Excerpt

In 2021, prostate, lung, and colorectal cancers (CRCs) will account for 46% of all incident cases in men, with prostate cancer (PCa) alone accounting for 26% of all diagnoses [1]. PCa has been the focus of much research in the last 2 decades with treatment advances, ranging from robot-assisted surgery to focal therapy and high-precision radiotherapy, with curative intent, to a growing number of new therapies for advanced disease [2], [3]. Molecular probes and imaging, particularly prostate-specific membrane antigen (PSMA) PET-CT, are likely to be increasingly important for PCa management. …

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.CrossRefPubMed

Lazzeri M, Guazzoni G. Focal therapy meets prostate cancer. Lancet. 2010;376(9746):1036–7.CrossRef

Roumeguère T, Aoun F, Albisinni S, Mjaess G. Antibodies targeting prostate-specific membrane antigen positive prostate cancer: from diagnostic imaging to theranostics. Curr Opin Oncol. 2021. https://doi.org/10.1097/CCO.0000000000000767.CrossRefPubMed

Ru Rüschoff JH, Ferraro DA, Muehlematter UJ, et al. What’s behind ⁶⁸Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05501-1.CrossRef

Lopci E, Lughezzani G, Castello A, et al. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. Clin Transl Oncol. 2021;23(1):172–8. https://doi.org/10.1007/s12094-020-02384-w.CrossRefPubMed

Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer-2020 update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–62. https://doi.org/10.1016/j.eururo.2020.09.042.CrossRefPubMed

Le JD, Tan N, Shkolyar E, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015;67:569–76.CrossRef

Lopci E, Guazzoni G, Lazzeri M. 68Ga prostate-specific membrane antigen PET/CT for primary diagnosis of prostate cancer: complementary or alternative to multiparametric MR imaging. Radiology. 2018;287(2):725–6. https://doi.org/10.1148/radiol.2017172607.CrossRefPubMed

Hoffmann MA, Miederer M, Wieler HJ, et al. Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18F-FEC PET/CT. Oncotarget. 2017;8(67):111073–83.CrossRef

10.

Donato P, Roberts MJ, Morton A, et al. Improved specificity with 68Ga-PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nucl Med Mol Imaging. 2019;46:20–30.CrossRef

11.

Werner RA, Thackeray JT, Pomper MG, et al. Recent updates on molecular imaging reporting and data systems (MI-RADS) for theranostic radiotracers-navigating pitfalls of SSTR- and PSMA-targeted PET/CT. J Clin Med. 2019;8(7):1060.CrossRef

12.

Hofman MS, Lawrentschuk N, Francis RJ, et al. proPSMA study group collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7.CrossRefPubMed

13.

von Eyben FE, Soydal C, von Eyben R. [68)Ga-PSMA PET/CT for patients with PSA relapse after radical prostatectomy or external beam radiotherapy. Diagnostics (Basel). 2021;11(4):622. https://doi.org/10.3390/diagnostics11040622.CrossRef

Titel: PSMA PET-CT: the winner takes it all
verfasst von: Massimo Lazzeri
Arturo Chiti
Publikationsdatum: 25.08.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2021
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05534-6

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

Evaluation of P-glycoprotein function at the blood–brain barrier using [18F]MC225-PET

Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas

Deep learning for whole-body medical image generation

Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Demonstration of in vivo estrogen receptor status with 16α- [18F]fluoro-17ß-oestradiol (FES) PET/CT in a rare case of benign metastasizing leiomyoma

Can someone look after my children while I write this COVID-19 paper?